My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: COG AAML08B1

Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)


This study will provide pre-clinical data (i.e., cytarabine drug sensitivity testing; functional polymorphisms in drug detoxification genes; biologic targets for drug therapy) to support the development of future therapeutic trials for TMD patients. Participants in this study have been diagnosed with a condition called Transient Myeloproliferative Disorder (TMD). TMD is found in young babies (less than 3 months old) with Down syndrome and is caused by abnormal blood cells that travel throughout the body. This study will utilize a mortality risk-based classification system to characterize the distinctive biological features of each TMD risk group and correlate these findings to outcome. Evidence based treatment recommendations have been included in Appendix V of this protocol to assist physicians with clinical management decisions and to encourage uniform treatment pathways for infants with TMD.

Fargo Region, Sioux Falls Region
Principal Investigator:
Kayelyn Wagner MD,Samuel Anim, MD
AML (Acute Myelogenic Leukemia)


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list